Quest Diagnostics Incorporated
Stock Forecast, Prediction & Price Target
Quest Diagnostics Incorporated (DGX) stock Price Target by analysts
$173.83
Potential downside: -4.92%
Quest Diagnostics Incorporated price prediction
What is Quest Diagnostics Incorporated stock analysts` prediction?
Quest Diagnostics Incorporated stock forecast: Based on 6 Wall Street analysts` predicted price targets for Quest Diagnostics Incorporated in the last 3 months, the avarage price target is $173.83, with a high forecast of $NaN. The average price target represents a -4.92% change from the last price of $182.83.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Quest Diagnostics Incorporated stock Price Target by analysts
Full breakdown of analysts given Quest Diagnostics Incorporated price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Patrick Donnelly Citigroup | 0% 0/1 | 11 months ago | $185 1.18% upside | $157.47 | TheFly | Previous targets (0) |
Michael Cherny Leerink Partners | 0% 0/1 | 11 months ago | $165 -9.75% downside | $157.47 | StreetInsider | Previous targets (0) |
Eric Coldwell Robert W. Baird | 0% 0/2 | 11 months ago | $182 -0.45% downside | $157.47 | StreetInsider | Previous targets (1) |
Stephanie Davis Barclays | 0% 0/2 | 11 months ago | $168 -8.11% downside | $157.47 | TheFly | Previous targets (1) |
Paige Meyer CFRA | 0% 0/1 | 11 months ago | $178 -2.64% downside | $157.46 | StreetInsider | Previous targets (0) |
David MacDonald Truist Financial | 0% 0/2 | 12 months ago | $165 -9.75% downside | $150.79 | TheFly | Previous targets (1) |
Ann Hynes Mizuho Securities | 0% 0/1 | about 1 year ago | $160 -12.48% downside | $143.21 | StreetInsider | Previous targets (0) |
Eric Coldwell Robert W. Baird | 0% 0/2 | about 1 year ago | $154 -15.76% downside | $140.96 | TheFly | Previous targets (1) |
David MacDonald Truist Financial | 0% 0/2 | about 1 year ago | $158 -13.58% downside | $144.11 | TheFly | Previous targets (1) |
Stephanie Davis Barclays | 0% 0/2 | over 1 year ago | $144 -21.23% downside | $137.55 | TheFly | Previous targets (1) |
Brian Tanquilut Jefferies | 0% 0/1 | over 1 year ago | $155 -15.22% downside | $127.42 | StreetInsider | Previous targets (0) |
Unknown Wells Fargo | N/A | over 2 years ago | $140 -23.42% downside | $143.29 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 2 years ago | $158 -13.58% downside | $155.5 | Benzinga | N/A |
Unknown Citigroup | N/A | almost 3 years ago | $125 -31.63% downside | $149.27 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 3 years ago | $142 -22.33% downside | $136.13 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 3 years ago | $150 -17.95% downside | $133.75 | Benzinga | N/A |
Ralph Giacobbe Citigroup | 0% 0/1 | over 3 years ago | $175 -4.28% downside | $140 | Pulse 2.0 | Previous targets (0) |
Pito Chickering Deutsche Bank | 0% 0/1 | over 3 years ago | $190 3.92% upside | $142.3 | Pulse 2.0 | Previous targets (0) |
Donald Hooker KeyBanc | 100% 1/1 | almost 4 years ago | $170 -7.01% downside | $161.75 | Investing | Previous targets (0) |
A.J. Rice Credit Suisse | 100% 1/1 | about 4 years ago | $150 -17.95% downside | $155.22 | TheFly | Previous targets (0) |
Quest Diagnostics Incorporated Financial Estimates
Quest Diagnostics Incorporated Revenue Estimates
Quest Diagnostics Incorporated EBITDA Estimates
Quest Diagnostics Incorporated Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $10.78B N/A | $9.88B -8.38% | $9.25B -6.38% | Avg: $9.76B Low: $9.71B High: $9.90B avg. 5.53% | Avg: $10.10B Low: $10.01B High: $10.18B avg. 3.45% | Avg: $10.62B Low: $10.52B High: $10.71B avg. 5.15% | Avg: $10.87B Low: $10.77B High: $10.96B avg. 2.35% |
Net Income
% change YoY
| $1.99B N/A | $946M -52.58% | $854M -9.72% | Avg: $970.18M Low: $924.34M High: $1.07B avg. 13.60% | Avg: $1.06B Low: $1.01B High: $1.20B avg. 9.95% | Avg: $1.25B Low: $1.23B High: $1.26B avg. 17.51% | Avg: $1.34B Low: $1.32B High: $1.35B avg. 7.00% |
EBITDA
% change YoY
| $3.15B N/A | $1.81B -42.68% | $1.73B -4.30% | Avg: $2.20B Low: $2.19B High: $2.23B avg. 27.29% | Avg: $2.28B Low: $2.26B High: $2.30B avg. 3.45% | Avg: $2.39B Low: $2.37B High: $2.41B avg. 5.15% | Avg: $2.45B Low: $2.43B High: $2.47B avg. 2.35% |
EPS
% change YoY
| $15.9 N/A | $8.12 -48.93% | $7.59 -6.52% | Avg: $8.51 Low: $8.18 High: $9.5 avg. 12.14% | Avg: $9.4 Low: $8.96 High: $10.66 avg. 10.44% | Avg: $11.09 Low: $10.97 High: $11.22 avg. 18.00% | Avg: $11.87 Low: $11.73 High: $12 avg. 7.00% |
Operating Expenses
% change YoY
| $1.82B N/A | $2.00B 9.68% | $1.61B -19.70% | Avg: $1.71B Low: $1.70B High: $1.73B avg. 6.31% | Avg: $1.77B Low: $1.75B High: $1.78B avg. 3.45% | Avg: $1.86B Low: $1.84B High: $1.87B avg. 5.15% | Avg: $1.90B Low: $1.88B High: $1.92B avg. 2.35% |
FAQ
What is Quest Diagnostics Incorporated stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 12.01% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is 924.34M, average is 970.18M and high is 1.07B.
What is Quest Diagnostics Incorporated stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 4.12% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $9.71B, average is $9.76B and high is $9.90B.
What is Quest Diagnostics Incorporated stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 11.89% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is $8.18, average is $8.51 and high is $9.5.
What is the best performing analyst?
In the last twelve months 6 analysts have been covering Quest Diagnostics Incorporated stock. The most successful analyst is Patrick Donnelly.